The relationship between different doses of dexamethasone administration (4, 5 and 6 mg) on neonatal cord blood cortisol levels to the incidence of respiratory distress syndrome in preterm neonates

Start Date01 Mar 2025

Sponsor / Collaborator

Faculty of Medicine Siriraj Hospital

TCTR20241104004

/ Not yet recruitingNot ApplicableIIT

Prevalence of HPV DNA detection among pregnant women: Promoting of self- Sampling HPV DNA testing for cervical cancer screening in pregnant women

Start Date01 Jan 2025

Sponsor / Collaborator

Faculty of Medicine Siriraj Hospital

TCTR20241008002

/ Not yet recruitingPhase 1/2IIT

Efficacy of Capsaicin Nasal Spray in Non-allergic rhinitis : A pilot study

Start Date01 Jan 2025

Sponsor / Collaborator

Faculty of Medicine Siriraj Hospital

100 Clinical Results associated with Faculty of Medicine Siriraj Hospital

0 Patents (Medical) associated with Faculty of Medicine Siriraj Hospital

157

Literatures (Medical) associated with Faculty of Medicine Siriraj Hospital

19 Feb 2025·ACS measurement science au

Multi-Pass Arrival Time Correction in Cyclic Ion Mobility Mass Spectrometry for Imaging and Shotgun Lipidomics

Author: Jariyasopit, Narumol ; Palmer, Martin E. ; Khoomrung, Sakda ; Duangkumpha, Kassaporn ; Sirivatanauksorn, Yongyut ; Goh, Jun Xian ; Wisanpitayakorn, Pattipong

Direct-infusion mass spectrometry (DI-MS) and mass spectrometry imaging (MSI) are powerful techniques for lipidomics research.However, annotating isomeric and isobaric lipids with these methods is challenging due to the absence of chromatog. separationRecently, cyclic ion mobility mass spectrometry (cIM-MS) has been proposed to overcome this limitation.However, fluctuations in room conditions can affect ion mobility multipass arrival times, potentially reducing annotation confidence.In this study, we developed a multipass arrival time correction method that proved effective across various dates, room temperatures, ion mobility settings, and laboratories using mixtures of reference standardsWe observed slight variations in the linear correction lines between lipid and nonlipid mols., underscoring the importance of choosing appropriate reference mols.Based on these results, we demonstrated that an accurate multipass arrival time database can be constructed from corrected t₀ and t_p for interlaboratory use and can effectively identify isomeric lipids in MSI using only a single measurement.This approach significantly simplifies the identification process compared to determining multipass collision cross-section, which requires multiple measurements that are both sample- and time-intensive for MSI.Addnl., we validated our multipass drift time correction method in shotgun lipidomics analyses of human and mouse serum samples and observed no matrix effect for the anal.Despite variations in dates, room temperatures, instruments, and ion mobility settings, our approach reduced the mean drift time differences from over 2% to below 0.2%.

19 Feb 2025·ACS bio & med chem Au

Development of Small Interfering RNA Loaded Cationic Lipid Nanoparticles for the Treatment of Liver Cancer with Elevated α-Fetoprotein Expression

Author: Kositamongkol, Prawat ; Srisawat, Chatchawan ; Rodponthukwaji, Kamonlatth ; Kunwong, Natsuda ; Metheetrairut, Chanatip ; Sirivatanauksorn, Yongyut ; Limjunyawong, Nathachit ; Nguyen, Kytai T. ; Ittiudomrak, Teeranai ; Duangchan, Kongpop ; Thaweesuvannasak, Mattika ; Tovikkai, Chutwichai ; Sirivatanauksorn, Vorapan ; Mahawithitwong, Prawej ; Punnakitikashem, Primana

α-Fetoprotein (AFP) is an oncogenic glycoprotein that is overexpressed in most patients with liver cancer.Moreover, it significantly affects tumorigenesis and progression, particularly by inhibiting programmed cell death or apoptosis.The treatment of liver cancer with chemotherapy is currently still in use, but its toxicity is a major concern.Alternatively, targeted therapy, especially small interfering RNA (siRNA)-based therapeutics that utilize siRNA to suppress target gene expression, is a promising cancer treatment approach that can help reduce such drawbacks.However, transporting siRNA into cells is a challenge due to its ease of degradation and limited cell membrane permeability.To overcome this limitation, we fabricated cationic lipid nanoparticles (cLNPs) to deliver AFP-targeted siRNA (siAFP) to AFP-producing liver cancer cells.Our results illustrated that these nanoparticles had a high capacity for siRNA encapsulation (>95%) and entered the cancer cells efficiently.Cell internalization of siAFP-loaded cLNPs resulted in the silencing of AFP mRNA expression and led to increased apoptotic cell death by inducing caspase-3/7 activity.This suggested that our cLNPs could be used as a powerful siRNA delivery carrier and siAFP-loaded cLNPs might be a useful strategy for treating liver cancer in the future.

01 Jan 2025·JCO Global Oncology

Efficacy and Safety of Short Intravenous Hydration for Preventing Nephrotoxicity From High-Dose Cisplatin: A Randomized, Open-Label, Phase II Trial

Article

Author: Kositamongkol, Chayanis ; Ithimakin, Suthinee ; Thephamongkhol, Kullathorn ; Jantarat, Apichart ; Srithongkul, Thatsaphan ; Phisalprapa, Pochamana ; Setakornnukul, Jiraporn ; Thamlikitkul, Lucksamon

PURPOSE:

The use of short hydration (SH) to prevent cisplatin-induced nephrotoxicity lacks substantive prospective evaluation. The aim of this study was to evaluate the safety and efficacy of SH, including those with head and neck cancer (HNC) who are at higher risks of mucositis that causes diminished oral intake.

METHODS:

This phase II randomized noncomparative trial included patients with cancer who were scheduled to receive high-dose cisplatin (≥60 mg/m 2 ) in combination with another chemotherapy or concurrently with radiotherapy. Patients were randomly assigned to receive either the SH or conventional hydration (CH) protocol. The primary end point was the proportion of patients with increased serum creatinine (SCr) after undergoing SH. Secondary end points included the severity of SCr elevation, adverse events, cisplatin modification as a result of nephrotoxicity, duration of hospital stay, quality of life (QoL), and cost.

RESULTS:

Among 100 enrolled patients, 64 and 36 patients underwent the SH and CH protocols, respectively. The median duration of chemotherapy infusion and intravenous hydration were 5.79 and 27.58 hours with SH and CH, respectively. A total of 32.8% and 33.3% of the SH and CH groups, respectively, experienced SCr elevation. Grade 2 SCr elevations were rarely observed in both groups (1.6% in SH, 2.8% in CH). Rate of cisplatin modification was similar between the two groups. Out of 82 patients with HNC, the rate of SCr elevation was comparable for both hydration protocols. The QoL scores were meaningfully higher in the SH group during the second cycle of cisplatin, although the overall direct medical costs were similar.

CONCLUSION:

The SH protocol is feasible and safe, with a remarkably reduced duration of administration. Thus, SH can be an alternative to CH in the prevention of cisplatin-related nephrotoxicity.

News (Medical) associated with Faculty of Medicine Siriraj Hospital

07 Dec 2020

·www.healthcareitnews.com

Huawei & Siriraj Hospital sign MoU to establish 5G powered smart platform for medical services

Huawei Technologies (Thailand) Co. Ltd. and the Faculty of Medicine, Siriraj Hospital, under Mahidol University, has signed the 5G Powered Smart Hospital Enabled with Cloud and AI Memorandum of Understanding (MoU) to establish a smart platform that will enhance innovative medical services. This MoU comes in response to the Faculty of Medicine Siriraj Hospital's mission to serve better by becoming a smart center that will apply integrated digital technologies using 5G infrastructure, artificial intelligence (AI), big data and cloud edge computing, in order to offer enhanced services. WHAT’S IT ABOUT Under the five-year agreement, Huawei will provide 5G technology to the Faculty, enabling the immediate upgrade of the existing infrastructure. It will also share knowledge and collaborate with Siriraj researchers and academic staff to enable Siriraj to operate more efficiently. Both parties will work together in other jointly-developed projects that may arise in the course of the MoU. Siriraj will participate with Huawei for further 5G ecosystem partnership cooperation to promote 5G technology and innovations, in the form of demonstration events and exhibitions. The hospital will also work with Huawei for joint academic sessions, to arrange training classes or technology sharing opportunities, and to study the latest technology topics including, but not limited to, 5G, AI and Cloud. THE LARGER TREND Siriraj Hospital, which is Thailand’s largest government hospital, is the first hospital in Southeast Asia to deploy two NVIDIA DGX A100 systems for medical research and clinical applications, Healthcare IT News reported. In South Korea, KT, the country’s largest telecommunications company and Samsung Medical Center are jointly developing a 5G-powered medical service as an initial step to establishing a 5G smart hospital. The two partners have been applying 5G on site to create better medical services since they signed a MoU in September 2019. ON THE RECORD “It is an honor for Faculty of Medicine Siriraj Hospital to partner with Huawei for this MoU that will raise the level and standards of our services and improve operational efficiency. This marks the initial step to establishing Thailand's first 5G smart state hospital,” said Prof. Dr. Prasit Watanapa, Dean of the Faculty of Medicine Siriraj Hospital, Mahidol University. “The healthcare sector can benefit immensely from smart innovations and infrastructure during this era of digitalization. We would like to accompany Thailand as it develops a strong, connected healthcare ecosystem in order to increase healthcare penetration in rural and remote communities and improve the quality of life of the people,” said Abel Deng, CEO of Huawei Technologies (Thailand).

100 Deals associated with Faculty of Medicine Siriraj Hospital

100 Translational Medicine associated with Faculty of Medicine Siriraj Hospital

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 28 Mar 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Phase 1

Current Projects

Drug(Targets)	Indications	Global Highest Phase

CD19 CAR-T (Faculty of Medicine Siriraj Hospital) ( CD19 )	Non-Hodgkin Lymphoma More	Phase 1
VP-001 (PYC Therapeutics) ( CNOT3 x PRPF31 )	Retinitis Pigmentosa 11 More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis